Cover Image
市場調查報告書

Valneva SE:產品平台分析

Valneva SE - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319999
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Valneva SE:產品平台分析 Valneva SE - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 35 Pages
簡介

Valneva SE 是製造疫苗及抗體的生物科技企業。在該公司產品中有日本腦炎、流行性流感、綠色膿菌、結核、困難腸梭菌、萊姆病等的疫苗。

本報告提供Valneva SE 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Valneva SE的基本資料

  • Valneva SE概要
  • 主要資訊
  • 企業資料

Valneva SE:R&D概要

  • 主要的治療範圍

Valneva SE:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Valneva SE:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Valneva SE:藥物簡介

  • VLA-43
  • Vaccine for Undisclosed Indication
  • VLA-84
  • Monoclonal Antibodies for Cancer
  • VLA-15
  • Antibodies for Pneumococcus Infections
  • Monoclonal Antibodies for Infectious Disease

Valneva SE:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型

Valneva SE:最近的開發平台趨勢

Valneva SE:暫停中的計劃

Valneva SE:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • IC-41
    • IC-47
    • Vaccine for Travelers Diarrhea
    • VLS-732
    • VLS-801

Valneva SE:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07674CDB

Summary

Global Markets Direct's, 'Valneva SE - Product Pipeline Review - 2015', provides an overview of the Valneva SE's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Valneva SE's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Valneva SE including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Valneva SE's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Valneva SE's pipeline products

Reasons to buy

  • Evaluate Valneva SE's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Valneva SE in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Valneva SE's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Valneva SE and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valneva SE
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Valneva SE and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Valneva SE Snapshot
    • Valneva SE Overview
    • Key Information
    • Key Facts
  • Valneva SE - Research and Development Overview
    • Key Therapeutic Areas
  • Valneva SE - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Valneva SE - Pipeline Products Glance
    • Valneva SE - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Valneva SE - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
    • Valneva SE - Drug Profiles
    • VLA-43
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLA-84
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLA-15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Pneumococcus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Valneva SE - Pipeline Analysis
    • Valneva SE - Pipeline Products by Target
    • Valneva SE - Pipeline Products by Route of Administration
    • Valneva SE - Pipeline Products by Molecule Type
  • Valneva SE - Recent Pipeline Updates
  • Valneva SE - Dormant Projects
  • Valneva SE - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • IC-41
      • IC-47
      • VLS-732
      • VLS-801
  • Valneva SE - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Valneva SE, Key Information
  • Valneva SE, Key Facts
  • Valneva SE - Pipeline by Indication, 2015
  • Valneva SE - Pipeline by Stage of Development, 2015
  • Valneva SE - Monotherapy Products in Pipeline, 2015
  • Valneva SE - Partnered Products in Pipeline, 2015
  • Valneva SE - Partnered Products/ Combination Treatment Modalities, 2015
  • Valneva SE - Out-Licensed Products in Pipeline, 2015
  • Valneva SE - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Valneva SE - Phase II, 2015
  • Valneva SE - Preclinical, 2015
  • Valneva SE - Discovery, 2015
  • Valneva SE - Pipeline by Target, 2015
  • Valneva SE - Pipeline by Route of Administration, 2015
  • Valneva SE - Pipeline by Molecule Type, 2015
  • Valneva SE - Recent Pipeline Updates, 2015
  • Valneva SE - Dormant Developmental Projects,2015
  • Valneva SE - Discontinued Pipeline Products, 2015
  • Valneva SE, Subsidiaries

List of Figures

  • Valneva SE - Pipeline by Top 10 Indication, 2015
  • Valneva SE - Pipeline by Stage of Development, 2015
  • Valneva SE - Monotherapy Products in Pipeline, 2015
  • Valneva SE - Partnered Products in Pipeline, 2015
  • Valneva SE - Pipeline by Top 10 Target, 2015
  • Valneva SE - Pipeline by Top 10 Molecule Type, 2015
Back to Top